BCAL Diagnostics Limited (ASX:BDX) has disclosed that director Jayne Shaw acquired 67,685 ordinary shares on 17 November 2026 via an on-market purchase for consideration of $4,036, according to a Change of Director's Interest Notice lodged with the exchange.
Key Points
- Director Jayne Shaw acquired 67,685 ordinary shares on 17 November 2026 at a total consideration of $4,036
- The acquisition was an on-market purchase with no securities disposed of
- The shares were acquired through Nabelle Pty Ltd <The Shaw Family A/C>, increasing that holding from 6,394,796 to 6,462,481 ordinary shares
- Shaw also holds 2,000,000 options with an exercise price of $0.25, expiring 8 October 2027
- The transaction did not occur during a closed period requiring prior written clearance
On-Market Purchase Details
The filing, submitted under ASX Listing Rule 3.19A.2, discloses that director Jayne Shaw completed an on-market purchase of 67,685 ordinary shares in BCAL Diagnostics Limited on 17 November 2026. The total consideration paid was $4,036. No securities were disposed of as part of the transaction. The previous Change of Director's Interest Notice for Jayne Shaw was dated 11 November 2026, according to the filing.
Director's Securities Holdings After the Change
Following the transaction, Jayne Shaw's interests in BCAL Diagnostics are held across several entities. Nabelle Pty Ltd <The Shaw Super Fund A/C> holds 22,986,662 ordinary shares, Nabelle Pty Ltd <Nabelle MMDC A/C> holds 1,742,025 ordinary shares, and Nabelle Pty Ltd <The Shaw Family A/C> holds 6,462,481 ordinary shares. OPSC Pty Ltd <The Hareda Foundation> holds 2,651,779 ordinary shares, and Jayne Shaw directly holds 2,022,638 ordinary shares. Shaw also retains 2,000,000 options with an exercise price of $0.25, expiring 8 October 2027.
Closed Period and Compliance Disclosure
The filing states that the interests in securities detailed in the notice were not traded during a closed period in which prior written clearance was required. As a result, the questions relating to prior written clearance and the date of any such clearance are recorded as not applicable in the filing. The notice was lodged with the exchange in accordance with section 205G of the Corporations Act and ASX listing rule 3.19A.2, with BCAL Diagnostics Limited identified by ABN 51 142 051 223.




Please wait processing your request...